用于增强肿瘤微环境中免疫应答的治疗剂和方法

人IgG1、IgG2和IgG4突变体在铰链结构域中具有突变并且表现出改变的与如FcγRIIB(CD32B)等Fcγ受体的结合亲和力。本文还提供了用于使用能够靶向免疫细胞表面受体和FcγRIIB两者的治疗剂选择性地激活受试者中的免疫应答的方法。 Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fcγ receptors such as FcγRIIB (CD32B). Also provided herein are...

Full description

Saved in:
Bibliographic Details
Format Patent
LanguageChinese
Published 10.06.2022
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:人IgG1、IgG2和IgG4突变体在铰链结构域中具有突变并且表现出改变的与如FcγRIIB(CD32B)等Fcγ受体的结合亲和力。本文还提供了用于使用能够靶向免疫细胞表面受体和FcγRIIB两者的治疗剂选择性地激活受试者中的免疫应答的方法。 Human IgG1, IgG2, and IgG4 mutants having mutations in the hinge domain and exhibiting altered binding activity to Fcγ receptors such as FcγRIIB (CD32B). Also provided herein are methods for selectively activating immune responses in a subject using a therapeutic agent capable of targeting both an immune cell surface receptor and FcγRIIB.
Bibliography:Application Number: CN202110948283